HCPCS Level II code J1740 designates the injectable formulation of ibandronate sodium at 1 mg per unit. Ibandronate is a bisphosphonate used in conditions affecting bone metabolism, and the HCPCS code is applied when the drug is supplied for injectable administration in outpatient settings. Nationally, accurate coding for drug units affects claims processing, coverage determination, and aggregate spending on specialty injectable medications.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for ibandronate injections, typical sites of service where J1740 is billed, and the payer landscape relevant to coverage and billing practice. The publication summarizes available benchmarks, common billing modifiers (listed elsewhere), and policy considerations that influence reimbursement and claim adjudication. It also outlines operational considerations for facilities and clinicians billing for injectable bisphosphonate therapy.

Data not available in the input are noted where applicable; the document focuses on national implications rather than state-specific rules.